The objectives of this study were to ascertain consumer knowledge and behaviour about hypertension and treatment and to compare these with health care providers' perceptions (of 'most' consumers). The design for the study was a problem detection study (PDS): focus groups and then survey. Focus groups and survey participants were convenience samples of consumers, doctors, nurses and pharmacists. The main outcome measures were agreement on a 5-point Likert scale with statements about consumers' knowledge and behaviour about high blood pressure and medication. The survey identified areas of consensus and disagreement between consumers and health providers. While general knowledge and concordance with antihypertensive therapy among consumers was good, consequences such as eye and kidney disease, interactions with herbal medicines, and how to deal with missing a dose were less well known. Side effects were a problem for over one-quarter of participants, and cost was a problem in continuing therapy. Half the consumers had not received sufficient written information. Providers overall disagreed that most consumers have an adequate understanding of the condition. They agreed that most consumers adhere to therapy and can manage medicines; and about their own profession's role in information provision and condition management. Consumers confirmed positive provider behaviour, suggesting opportunities for greater communication between providers about actions taken with their consumers. In conclusion, the PDS methodology was useful in identifying consumer opinions. Differences between consumer and provider responses were marked, with consumers generally rating their knowledge and behaviour above providers' ratings of 'most' consumers. There are clear gaps to be targeted to improve the outcomes of hypertension therapy.
Introduction
As one of the four arms of Australia's National Medicines Policy, many existing and planned strategies aim at improving how Australians actually use medicines.
1,2 Quality use of medicines (QUM) is high on the clinical and policy agenda in Australia and elsewhere. [1] [2] [3] [4] In order to understand what consumers know and believe about their disease and treatment, it is essential to obtain their views and perceptions. [5] [6] [7] [8] [9] The views and perceptions of health care providers about these same issues can also be sought and, ideally, interventions can then be designed to bridge any gaps and match knowledge and information needs with provision. [10] [11] [12] Reports, however, have described a gap between consumer and provider perceptions of the issues and problems faced by consumers. 13 Most research tends to ask what providers want to know and what providers think is important.
14 Consequently, there tends to be greater emphasis on what health providers think is important in the care of their patients.
Although it has been found that education alone will not significantly increase compliance, some knowledge regarding the condition and reasons for treatment is necessary for behaviour change. [15] [16] [17] [18] It is clear, however, that this knowledge should be carefully matched to that already possessed by the individual and should be designed to test or extend that knowledge, not merely to repeat known facts.
Expert panels or focus groups conducted with consumers have been used to ascertain specific information and education needs of the general community with respect to their medicine use. 14 Focus groups of consumers have been used to identify barriers to drug use in patients with congestive heart failure, describing, for example, the importance of closer consumer-health provider relationships, social support and increasing the consumers' knowledge. 19 While these methods are valuable, assessment of consumer issues using larger samples has not been carried out. 13 At least one novel method exists that attempts to redress this discrepancy. The problem detection study (PDS) is accepted as a tool for qualitative health service research, and has been used in developing effective QUM educational campaigns elsewhere since 1991. [10] [11] [12] Its use outside Europe, however, has not been reported and its use for people with hypertension has not been previously reported.
This project applied the PDS method to the major health problem of hypertension. Hypertension, frequently an asymptomatic disease, can lead to many secondary causes of morbidity and mortality. 20, 21 Cardiovascular disease accounts for 40% of deaths in Australia, 22 creates large costs for health care systems, and places a significant burden on individuals and the community because of resulting disabilities. 21, 23 During the period 1999-2000, almost 3 million Australians over the age of 25 years had hypertension, or were taking medication for it. 24 Of all those with hypertension (defined as diastolic blood pressure 490 mm Hg), one Australian study reported that 47% of men and 23% of women were not taking any medications for their high blood pressure. 20 It is important that hypertension is effectively treated. It is also important to discover the reasons, from consumers, why medication is not used optimally for this condition. Little is known about the consumer's perspectives regarding the management of hypertension, and whether these views align with the perspectives of the health professionals providing treatment for the condition. [25] [26] [27] This project had two principal aims: to test the PDS methodology and to use the method to derive insights into potential gaps between consumer and provider views about hypertension and its treatment. The detection function of the PDS can inform interventions aimed at improving the management of hypertension.
Methods
The PDS in hypertension was conducted in Brisbane during 2001. Ethics approval for the study was obtained from the Medical Research Ethics Committee at the University of Queensland (Approval Number: B/460/PHARM/00). An extensive literature review was initially conducted using MEDLINE Three levels of participation from informed consenting health providers and consumers were required throughout the duration of the project: a project advisory group; participants for focus groups who would identify and confirm issues for subsequent investigation; and a wider sample to complete a written survey of issues relating to the treatment of hypertension. Consumer participants for the focus groups and the advisory panel were recruited through a hypertension association, and health professionals through interest groups, personal contacts and professional associations. All participants were volunteers, with the advisory panel being selected for their representation of different groups. For completion of the resulting survey, health providers throughout Brisbane (general practitioners, community and specialist nurses, and pharmacists) and consumers currently diagnosed with hypertension and taking at least one antihypertensive medication were invited to participate in the project. Survey responses were anonymous and confidential. The project advisory group met in the planning stages of the study, and was reconvened after initial data analysis was completed, in order to assist in interpretation.
Four focus group meetings of 8-10 participants each, separately involving pharmacists, consumers, doctors and nurses, were held. These focus groups were semistructured, with open questions 'seeded' to start the discussion. Each lasted for approximately 2 h. The discussion was recorded manually, the issues collated and the major themes drawn out. The focus group data indicated five principal areas of interest: understanding the condition; understanding the medication therapy; informationseeking behaviours and needs; understanding lifestyle contributors; and adherence and review behaviours. These broad themes, together with the results of the critical review of the published literature, suggested possible survey statements. The project advisory group confirmed the final list of 29 survey items on which the Likert-type 5-point scale (agree/disagree) was based. The survey items were deliberately listed on the survey in a random order (ie no clusters around the five principal areas of interest) and the survey order was the same for all groups of participants, consumer or health care provider.
Appropriately worded versions of the survey items were produced for health providers (referring to 'most consumers') and for the consumer participants (referring to the participant). All surveys were accompanied by a prepaid addressed envelope. Each survey requested anonymous demographic data about the participants and their experience with hypertension. A total of 30 community phar-macists were recruited to provide the surveys to any consenting patient taking at least one antihypertensive medication. Each pharmacy was requested to hand out a maximum of 50 surveys to consumers over a 30-day period. Most did not give out 50 in this period.
In addition to the consumer surveys, 210 health provider surveys were distributed to pharmacies (60 pharmacies in total received this survey, extra were distributed as some pharmacies employ more than one pharmacist: given an average of 1.5 pharmacists per target pharmacy, an estimate of the available sample size is 90); 118 health provider surveys to nurses in hospital and community settings; and 18 health provider surveys to general practitioners identified by the GP on the advisory group. Returned questionnaires were examined for completeness and data were coded and entered in an electronic database that enabled export to the SPSS statistical analysis package.
Statistical analyses
There were two main categories of respondents to the surveyFconsumers and health providers (pharmacists, nurses and doctors). The survey generated numeric and text dataFthe numeric at either the ordinal or interval level. Ordinal data were analysed using non-parametric statistical tests. Differences between the groups were determined using the Kruskal-Wallis test. Interval data were analysed using ANOVA. Where differences existed, post hoc range and pairwise multiple comparisons were used to determine which means differed (Scheffé's tests). Measures of central tendency for the numeric data were calculated as the mean, standard error of the mean, and median score, while measures of dispersion were calculated as frequency counts or percentages. To enable comparability with other published PDS, the data were also analysed by the percentage of positive, neutral or negative scores for each respondent group in the sample.
Statistical analyses were performed using SPSS version 10.0, including data checking for 'out of range' values and for assumptions of normality where inferential statistics were required. Normality was tested using the Kolmogorov-Smirnov statistic with a Lilliefors significance correction. By convention, statistical significance (P) values for all analyses was determined as 0.05.
Results
There were 287 consumer surveys returned. Those incorrectly completed, for example missing data, were excluded. This left 264 valid consumer surveys for analysis. Gender responses by age, reported number of medicines and their duration are illustrated in Table 1 . There were no statistically significant differences between the mean ages for males and females, the time they reported taking hypertensive medication, nor the mean number of medications reported as taken for hypertension. In total, 50% of males (n ¼ 77) and 52% of females (n ¼ 56) reported taking only one antihypertensive medicine, 34% of males (n ¼ 53) and 32% of females (n ¼ 34) reported two concurrent antihypertensives, and 13% of males (n ¼ 20) and 12% of females (n ¼ 13) reported taking three or more medicines (up to seven in one male) concurrently for their hypertension. In the sample, 175 (106 male and 68 female) consumers reported taking hypertensive medicine for more than 4 years, and the remaining (47 male and 41 female) consumers for less than 4 years.
Of all consumers 49% (n ¼ 129), reported that they had received printed information on high blood pressure. A low 1.0% (n ¼ 3) of the consumer respondents (all males) reported that they currently belonged to a high blood pressure support group. Some respondents (2.7%, n ¼ 7) reported they were taking herbal medicines for their high blood pressure. These were more likely to be female (4.6% of total female sample) than male (1.3% of total male sample). In all, 13% of consumers (n ¼ 34) reported that they were currently measuring their blood pressure at home (14% males and 12% females).
There were 133 valid health provider surveys completed out of an anticipated 230 (18 GPs, 118 nurses and approximately 90 pharmacists). Health provider data by practice setting and number of hypertensive patients seen per week are presented in Table 2 .
Pharmacists had spent less time than doctors in practice overall. Analysis of the nurses' ranked scores by practice setting (as over a quarter practised in hospitals) indicated that significant differences existed only in whether they considered that most consumers receive sufficient written information about their antihypertensive medicines. More community-than hospital-based nurses thought this (w 2 ¼ 6.54, df ¼ 1, P ¼ 0.011). Whether most consumers understand that hypertension is the same as high blood pressure, more hospital than community-based nurses thought this (w 2 ¼ 4.26, df ¼ 1, P ¼ 0.039). There were no other differences based on site of practice.
To enable comparability with other PDS, the data are reported by the total percentage of consumers and combined health providers marking agree (4) and strongly agree (5) on the 5-point Likert scale (Table 3 ). The Kruskal-Wallis statistic on ranked median scores for consumers and categories of health professionals revealed many significant differences between groups. This reflects the wide disparity in percentage agreement between consumers and the provider group seen on many of the survey items, for example knowledge of target blood pressure or kidney and eye disease consequences. Table 3 includes all the general data obtained from the groups; however, there were also some notable differences within subgroups. For example, for consumers, significantly more females than males agreed that they understood that hypertension is the same as high blood pressure (w 2 ¼ 8.24, df ¼ 1, P ¼ 0.004), and more males than females disagreed with the statement that they understood high blood pressure can cause kidney disease (w 2 ¼ 4.05, df ¼ 1, P ¼ 0.044). Most consumers report they understand that over-the-counter (OTC) medicines can interact with their blood pressure medicines, but gender differences reached statistical significance (w 2 ¼ 5.04, df ¼ 1, P ¼ 0.025) with more females than males agreeing with this statement. Only 49% of consumers reported agreement with the possible interaction with herbal preparations, with more females agreeing than males (w 2 ¼ 8.64, df ¼ 1, P ¼ 0.003). Most consumers agreed that they have enough assistance to remember to take their medicines. Slightly fewer felt confident in managing their medicinesFgender differences reaching statistical significance (w 2 ¼ 5.58, df ¼ 1, P ¼ 0.018)Fwith more females than males reporting agreement with this statement.
Only 5% of consumers (n ¼ 14) agreed that they are sometimes influenced by friends or family to stop taking their blood pressure medicines, and in this group, females were significantly more likely to be influenced than males (w 2 ¼ 8.39, df ¼ 1, P ¼ 0.004). This is contrasted with 48% of providers (n ¼ 64) who agreed that most consumers are sometimes influenced to stop in this way.
Most consumers agreed that they regularly review their blood pressure medicines with their doctor, and significantly more females than males (w 2 ¼ 4.33, df ¼ 1, P ¼ 0.037) agreed with this. Only 35% of providers (n ¼ 47) agreed that this occurs for most consumers, but there were differences between the provider categories in this regard, with 67% of doctors (n ¼ 12) agreeing, and 25% of the pharmacists (n ¼ 13) and 34% of the nurses (n ¼ 22) disagreeing that consumers regularly reviewed their antihypertensives with their doctor.
Nearly 80% of consumers (n ¼ 221) agree that their doctor takes a planned approach to their blood pressure medicines; however, this number declines in relation to whether medicine changes and brand substitution are adequately explained. While 50% of providers (n ¼ 67) agree that therapy is planned, there are differences between provider categories, with pharmacists and nurses not agreeing as strongly as doctors, that doctors take a planned approach to antihypertensive medicines. In relation to brand substitution, pharmacists agreed, while nurses and doctors disagreed, that this was adequately explained to consumers.
The consumer group was further examined to determine if there were differences in survey scores for those in treatment for hypertension for different time periods: 175 (106 male and 68 female) consumers reported taking hypertensive medicine for longer than 4 years, and 89 (47 male and 41 female) consumers for less than 4 years. The longer treatment time group reported a significantly stronger agreement (w 2 ¼ 3.56, df ¼ 1, P ¼ 0.001) than the group treated for less than 4 years in their understanding that hypertension is synonymous with the term high blood pressure, in understanding what their target blood pressure is, and in understanding that high blood pressure can cause kidney disease. The subgroup receiving treatment for less than 4 years was significantly less certain than the longer treatment group (w 2 ¼ 4.12, df ¼ 1, P ¼ 0.001) that changes in their blood pressure medicines are adequately explained to them, and that their health care providers have helped them achieve lifestyle changes.
Confidence in knowing what to do if a dose is missed is significantly less in the 'under 4 years' subgroup than their more experienced counterparts (w 2 ¼ 8.47, df ¼ 1, P ¼ 0.001), while both groups disagree that friends or family experiences influence their continued use of hypertensive medicines, and the 'over 4 years' subgroup is significantly more certain of this. Discussion A significant message of this study is that in almost all the items (Table 3) , consumers ranked the issue differently to health professionals. This finding is consistent with earlier applications of the PDS and highlights that if interventions to assist consumers were developed solely from a health professional perspective, important issues to consumers could be missed. [9] [10] [11] [12] 27, 28 The PDS methodology was successfully conducted in the Australian environment and would be a transportable method for other groups and for other countries to consider when seeking valuable insights into consumer perceptions and behaviour.
Care should be taken, however, with extrapolation of these specific data. This was a convenience sample of voluntary participants, with an average length of time taking medicine for hypertension of 11 years: a sample well experienced in the condition and its treatment. Given that surveys were distributed through pharmacies to people receiving antihypertensive medicine, the sampling technique will also be biased to those who adhere to their medicine treatment. It would be interesting to sample a group more recently diagnosed, as this study showed that those with less experience tended to be less certain of some aspects of hypertension and its treatment. However, any educational intervention would need to be designed so as not to 'talk down' to those who had knowledge about the condition and its consequences, as health professionals thought that consumers had substantially less knowledge than they actually reported.
Patient education can sometimes have little impact on individuals owing to commonly held beliefs of, and activities carried out by, health care providers. Assumptions include that education alone will produce behaviour change, 29 leading to over-reliance on one or two education strategies only (eg a brief lecture), efforts too short to achieve long-term behaviour change, and failure to undertake a behavioural diagnosis to select appropriate educational strategies for particular individuals. 18, 30, 31 To achieve long-lasting behavioural modifications, educational activities lasting for prolonged periods and of a diverse nature are required. 17, 18 Although it has been found that education alone will not significantly increase compliance, some knowledge regarding the condition and reasons for treatment is necessary for behaviour change. 15, 16 However, this knowledge should be carefully matched to that already possessed by the individual and should be designed to test or extend that knowledge, not merely to repeat known facts.
It is interesting that consumers tended to agree more that their therapy is planned and explained than health providers do. Consumers supported the relevant health providers' perceptions more than the other health providers do. For example, consumers agreed with pharmacists that brand substitution is explained (nurses and doctors did not agree) and agreed with doctors that a planned approach to medicines is undertaken and changes are adequately explained (nurses and pharmacists did not agree). These results suggest some interesting insights. Among each of the provider groups, there is less confidence that others have performed these tasks. This may demonstrate that there is relatively little information exchange between the provider groups about planned approaches, including explanation to the consumer of changes to therapy. It may also indicate that the health providers do not take account of the services provided to consumers by the other providers. Perhaps better interdisciplinary Most consumers are sometimes influenced by friends or family to stop taking medicines due to their experiences.
Categories: AFknowledge/understanding of the condition of hypertension, BFunderstanding of the medicine therapy, CFinformation-seeking behaviour/needs, DFunderstanding of lifestyle contributors, EFadherence and review behaviours.
communication and collaboration about the actions and plans implemented for individual consumers might help to bridge this difference in perceptions. Using the general practitioner as a principal health provider and utilizing the skills of other health providers (eg pharmacists and nurses), a comprehensive approach to treating and educating the consumer can be achieved. [32] [33] [34] Pharmacists can monitor patients, work together with general practitioners to review all aspects of pharmacotherapy, and help the consumer individually by tailoring regimens and educating on all components of therapy including lifestyle changes. [35] [36] [37] [38] Nurses can contribute to the health team by providing support to the general practitioner, monitoring of blood pressure and other aspects of therapy, providing education to consumers individually, and forming valuable links with social support networks in families, workplaces and the greater community. 39, 40 These results suggest opportunities for targeted information about interactions between blood pressure medicines, OTC and especially herbal preparations. In addition, a clear explanation of changes to therapy, including OTC and complementary medicines, is needed, including information exchange between providers. Consumers commencing therapy for hypertension may benefit from appropriately targeted information about the risk/ benefits and potential interactions of antihypertensive medication.
While over half of the consumers reported that side effects are not a problem to them, 26% say they are. Providers are almost universally in agreement with the statement that side effects can cause problems; however, their question may have been too generic as it is hard to disagree that side effects can cause problems per se. The lower consumer score may indicate experienced consumers who have perhaps sorted out any adverse effects through changes and adaptations. This analysis gains some support by examining the subsample of consumers with 4 years or less time on hypertension medication. For this group, side effects are more of a problem than for their more experienced peers. It could also be that adverse effects are not being recognized as such. It would be an ineffective use of resources, however, to base a whole campaign around the perception by health providers of side effects as a major issue. There are more important issues that consumers are concerned about. The highest median score in the survey by providers was that side effects can cause problems; however, the ranking as a problem rated second lowest for consumers. The consumer results are consistent with the literature on the relations between side effects and adherence. For example, two separate studies found that only 7% of consumers indicated that side effects were enough of a problem to discontinue therapy. 41, 42 With respect to information seeking, only half of the consumers felt they had received sufficient written information and a similar number thought that information for their family would be useful. These results suggest that there are substantial opportunities for providing further information to consumers and their families about hypertension and medicines. Extensive social support and education (usually given to the spouse) has been demonstrated to improve the compliance behaviours and blood pressure control of hypertensive patients. [43] [44] [45] The media was not perceived by many as a useful source of information, while only one-quarter of consumers agreed that it was easier to get information themselves rather than waiting for providers to supply it. This suggests that, despite the multiple information sources now available to consumers, there is clearly still a primary role for health providers to supply information. Unfortunately, support groups were not recognized by consumers as useful information resources. This could indicate the low penetration of awareness of these groups (only 1% of the consumers belonged to one), although the health providers agreed (50%) that these would be useful. This suggests that providers are supportive of such information, but may have little knowledge of the extent of consumer involvement in support groups. It could be helpful to consumers if health providers could distribute information about these support groups.
For understanding lifestyle contributors, most consumers agreed that they understand how weight and diet affects their blood pressure, but while half of the providers agree that consumers understand the relation between weight and blood pressure, only one-third agree on consumer understanding of the relation between diet and blood pressure. Half of the consumers agreed that it is helpful for providers to reinforce the need for lifestyle change, but less than half agree that providers have helped them achieve these changes. This indicates an opportunity for providers to help with these factors in a strategic manner, with individualized behaviour change approaches.
The literature shows that information, education and reinforcement can all contribute to effective change, but these need to be delivered in targeted and coordinated ways, based on the individual. 46, 47 Care needs to be taken in utilizing social support through 'fear tactics,' for example, by emphasizing catastrophic consequences of inadequate dietary compliance. There is often miniscule benefit and occasional 'backfires' for the patient, resulting in excess fault-finding and nagging. 15, [48] [49] [50] Importantly for adherence and review behaviours, consumers overwhelmingly agreed that they have enough assistance to remember to take, and feel confident in managing, their medicines. However, this significantly declines for the less experienced group (see Results). Interestingly, provider agreement with these items is lower in all cases.
Almost all consumers agree that they continue to take their medicines when asymptomatic, and three-quarters of the providers agree that most consumers do so. This is reassuring as this has been identified as one of the main reasons for stopping therapy. However, this is a very different finding to that reported in the literature. For example, one study found that almost 40% of all patients who had dropped out of therapy did so because they 'felt' good without using antihypertensive medications. 41 Several studies reviewed by Garfield and Caro 51 demonstrated that the asymptomatic nature of hypertension is still one of the most significant causes of noncompliance. A possible explanation for the consumer results is the sample bias towards long-term medicine users recruited though pharmacies. However, the provider result suggests either a very different adherence pattern in the community, or a low understanding of how the asymptomatic nature of hypertension influences adherence.
Consumers and providers disagree that consumers are confident in knowing what to do if they miss a hypertension medicine dose, with three-quarters of consumers saying they are confident and only 10% of providers agreeing. Almost 20% of this experienced sample of consumers say they do not know what to do if they miss a doseFa potential problem in the trend to single daily dose regimens, and a demonstrated need for better medicines information.
Over 30% of consumers agree that medicine cost is a problem in continuing therapy; a similar number of providers agree. This is a concern as this could be another reason for stopping therapy. Previous research has found that 12% of people discontinued antihypertensive medications because of cost, and another group found this figure to be 2%. 41, 42 Again, this needs further investigation in a group of patients commencing antihypertensive therapy.
Consumers do not agree that they are sometimes influenced by the experiences of friends or family to discontinue their medicines. They are very clear about this, and this is significantly different from the view of the health providers, who agree that consumers are influenced by friends/family experiences and stop taking their medicines. This was the item with which consumers agreed least and may again reflect aspects of sample bias toward experienced, adherent medicine users. It may be that for these consumers their family and friends are supportive of therapy, and this social support would be consistent with the overall reported adherence of the group.
Conclusions
In this PDS, a questionnaire was successfully developed to compare consumer attitudes and knowledge about hypertension to those of health providers. The survey was developed from focus group information as well as from data in the literature. The results from administration of the survey revealed significant differences in perceptions between experienced hypertensive consumers and health care providers (doctors, pharmacists and nurses). Interventions need to be developed that are based on identified consumer opinions and issues, together with the different perceptions of health care providers.
